Enigma Biomedical USA Receives MJFF Grant for Novel α-Synuclein PET Biomarker
Enigma Biomedical USA Awarded $2 Million Grant from The Michael J. Fox Foundation to Advance Novel α-Synuclein PET Imaging Biomarker for Parkinson’s Disease Enigma Biomedical USA (EB USA) today announced…
Vyome Appoints Dr. Aditya Bardia as Senior Medical Advisor
Vyome Holdings Announces Appointment of Renowned Oncologist Dr. Aditya Bardia as Senior Medical Advisor to Advance VT-1953 for Malignant Fungating Wounds Vyome Holdings, Inc. (“Vyome”) (NASDAQ: HIND), a clinical-stage healthcare…
Revised Announcement: Pathway to Cures Invests in SeraGene Therapeutics
Pathway to Cures Invests in SeraGene Therapeutics The fifth paragraph of the original release dated November 19, 2025, should read: Pathway to Cures joins Hextwo Capital as early investors in…
SHORE Study Confirms HeartCare’s Prognostic Power in Transplant Patients
CareDx Announces Publication of New SHORE Study Demonstrating the Prognostic Power of HeartCare® for Heart Transplant Recipients in the Journal of Heart and Lung Transplantation CareDx, Inc. (Nasdaq: CDNA), a…
Kelonia Unveils First-in-Human In Vivo BCMA CAR-T Data at ASH 2025
Kelonia Therapeutics Announces Late-Breaking Oral Presentation Showcasing First-in-Human Data for KLN-1010, an In Vivo BCMA CAR-T Gene Therapy, at ASH 2025 Kelonia Therapeutics, Inc., a clinical-stage biotechnology company advancing a…
Microsize and Schedio Group Announce Acquisition of Lonza’s Micro-Macinazione Facility in Switzerland
Microsize and Schedio Group Sign Agreement to Acquire Lonza’s Micro-Macinazione Facility in Switzerland, Advancing a Transatlantic Particle Engineering Platform Microsize, a prominent contract development and manufacturing organization (CDMO) known for…
AstraZeneca to Invest $2B in Maryland Manufacturing, Create 2,600 Jobs
AstraZeneca Announces $2 Billion Expansion to Strengthen Maryland Manufacturing, Advance Innovation, and Support 2,600 Jobs AstraZeneca today unveiled a major strategic investment plan totaling $2 billion to expand its long-standing…
U.S. FDA Grants Approval to PADCEV® and Keytruda® Combination for Select Bladder Cancer Patients
FDA Authorizes PADCEV® + Keytruda® Regimen for Eligible Individuals with Bladder Cancer Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503; President and CEO: Naoki Okamura, “Astellas”) announced that…
Parabilis Medicines Reports Encouraging Early FOG-001 Data in ACP at SNO 2025
Parabilis Medicines Announces Compelling Preliminary Clinical Results for FOG-001 in Adamantinomatous Craniopharyngioma at SNO 2025 Parabilis Medicines, a clinical-stage biopharmaceutical company dedicated to developing transformative therapies for patients with cancer,…
Blue Lake Biotech to Resume Enrollment in BLB201 Toddler Trial
Blue Lake Biotechnology Announces FDA Clearance to Resume Enrollment of RSV-Negative and Younger Toddlers in Phase 1/2a Clinical Trial of BLB201 Blue Lake Biotechnology, Inc., a clinical-stage company pioneering intranasal…
AGC Biologics to Produce AAVantgarde’s Dual-Vector Gene Therapies
AGC Biologics and AAVantgarde Forge New Manufacturing Partnership to Advance Dual-Vector Gene Therapies for Inherited Retinal Diseases Following AAVantgarde Bio’s recent completion of a successful Series B financing round, the…
BeOne Medicines Highlights Advances in B-Cell Malignancy Treatments at ASH 2025
BeOne Medicines Demonstrates Scientific Leadership in B-Cell Cancers at ASH 2025 BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a rapidly expanding global oncology innovator, is set to showcase…